Andrew Hykes compensation by year
Inari Medical Summary Compensation Table · all 3 fiscal years held| Component | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Salary | $450,000 | $500,000 | $700,000 |
| Bonus | $292,500 | $0 | $0 |
| Stock awards | $1,812,192 | $2,263,932 | $2,606,744 |
| Option awards | $0 | $0 | $937,488 |
| Non-equity incentive | $0 | $354,250 | $826,000 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $8,335 | $9,532 | $13,133 |
| Total | $2,563,026 | $3,127,714 | $5,083,365 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Inari Medical, Inc. DEF 14A filed March 13, 2024, accession 0001193125-24-066805, and prior-year filings.
How this page was built: the Inari Medical, Inc. filed document, accession 0001193125-24-066805. Every figure is read from that document and cited to the page and table it appears in. Filed March 13, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 34,912 | $2,266,487 | — |
| RSU | 14,940 | $969,905 | — |
| RSU | 4,008 | $260,199 | — |
| RSU | 16,719 | $0 | — |
| RSU | 161,100 | $0 | — |
| Option | 27,063 | — | $56.00 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Inari Medical, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
19 Form 4 lines since the FY2023 proxy (filed March 13, 2024)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-02-19 | Disposition to the issuer derivative | — | 44,693 | — | 0 |
| 2025-02-19 | U | — | 1,550 | — | 0 |
| 2025-02-19 | U | — | 1,550 | — | 0 |
| 2025-02-19 | U | — | 1,550 | — | 0 |
| 2025-02-19 | U | — | 1,000 | — | 0 |
| 2025-02-19 | Grant or award | — | 20,393 | — | 717,637 |
| 2025-02-19 | Disposition to the issuer derivative | — | 36,085 | — | 0 |
| 2025-02-19 | U | — | 717,637 | — | 0 |
The 8 most recent of 19 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Inari Medical discloses, by trigger · FY2023| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $700,000 | $0 | $29,404 | $1,429,404 |
| Change in control, no termination | $0 | $3,496,591 | $0 | $3,496,591 |
| Change in control and involuntary termination | $1,400,000 | $3,737,002 | $58,809 | $6,656,811 |
Per the Potential Payments Upon Termination or Change in Control table in Inari Medical, Inc.'s FY2023 proxy. Estimates as the company printed them; a dash means it printed no figure.
Inari Medical’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Andrew Hykes · this page | Chief Executive Officer | $5,083,365 |
| Thomas Tu | Chief Medical Officer | $2,495,947 |
| Mitchell Hill | Chief Financial Officer | $2,494,947 |
Board service
Inari Medical board · FY2023How this board is paid
Company policy: Inari Medical pays directors a $50,000 cash retainer and $160,000 in RSUs. As stated in Inari Medical's FY2023 proxy.
The full Inari Medical compensation record
free company briefThis page is one person within Inari Medical's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Inari Medical proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Inari Medical's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.